Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: January 13, 2020
Reporting Period: Single event date (January 13, 2020)
Business Overview: The registrant is an emerging growth company incorporated in Delaware, with principal executive offices in Wayne, PA. The company's common stock trades on The Nasdaq Stock Market under the symbol "ACRS."
Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document serves solely to disclose a regulatory update regarding a company presentation.
Material Changes
Item 7.01 Regulation FD Disclosure: On January 13, 2020, the Company updated its company overview presentation. A copy of this presentation is furnished as Exhibit 99.1 to this report. No other material changes to operations or financial status are reported in this specific filing.
Guidance, Outlook, and Risks
Management Commentary: The filing references an updated company overview presentation (Exhibit 99.1) but does not include the text of the presentation itself within the body of the 8-K.
Legal Disclaimer: In accordance with General Instruction B.2 of Form 8-K, the information contained in Item 7.01 and Exhibit 99.1 is not deemed "filed" for purposes of Section 18 of the Exchange Act and is not subject to the liability of that section. It shall not be deemed incorporated by reference in any other filings unless expressly set forth by specific reference.
Key Facts for Investor Verification
- Verify the content of the updated company overview presentation by reviewing Exhibit 99.1 attached to this filing.
- Confirm that the presentation is not automatically incorporated by reference into other SEC filings unless explicitly stated.
- Note that this filing contains no new financial data or operational results for the period.